Sanofi (NASDAQ:SNY) Shares Sold by Qtron Investments LLC

Qtron Investments LLC reduced its position in Sanofi (NASDAQ:SNYFree Report) by 13.2% in the 4th quarter, reports. The firm owned 23,462 shares of the company’s stock after selling 3,554 shares during the quarter. Qtron Investments LLC’s holdings in Sanofi were worth $1,167,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in SNY. Millington Financial Advisors LLC lifted its stake in shares of Sanofi by 5.2% in the 3rd quarter. Millington Financial Advisors LLC now owns 18,091 shares of the company’s stock valued at $970,000 after purchasing an additional 895 shares during the period. Ieq Capital LLC raised its position in Sanofi by 13.2% during the third quarter. Ieq Capital LLC now owns 4,962 shares of the company’s stock worth $266,000 after acquiring an additional 577 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Sanofi by 12.1% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,880 shares of the company’s stock worth $208,000 after acquiring an additional 418 shares during the period. Savant Capital LLC acquired a new position in Sanofi during the third quarter worth $207,000. Finally, Atria Investments Inc raised its position in Sanofi by 14.9% during the third quarter. Atria Investments Inc now owns 74,791 shares of the company’s stock worth $4,012,000 after acquiring an additional 9,694 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Price Performance

Sanofi stock opened at $49.03 on Friday. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.72. The firm has a market capitalization of $124.04 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 1.52 and a beta of 0.61. The company has a fifty day simple moving average of $48.30 and a 200-day simple moving average of $48.33. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNYGet Free Report) last released its earnings results on Thursday, April 25th. The company reported $0.96 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.96. Sanofi had a net margin of 10.52% and a return on equity of 26.25%. The business had revenue of $11.36 billion during the quarter, compared to analyst estimates of $11.75 billion. On average, equities analysts anticipate that Sanofi will post 4.13 EPS for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a $1.478 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a dividend yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is currently 74.37%.

Analysts Set New Price Targets

SNY has been the subject of a number of research analyst reports. cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

View Our Latest Analysis on SNY

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Read More

Want to see what other hedge funds are holding SNY? Visit to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.